Comparative Pharmacology
Head-to-head clinical analysis: BACLOFEN versus STRIFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACLOFEN versus STRIFON FORTE DSC.
BACLOFEN vs STRIFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Caffeine is a central nervous system stimulant that acts as an antagonist at adenosine receptors (A1 and A2A subtypes), thereby reducing the inhibitory effects of adenosine. Dihydroergotamine is an ergot alkaloid with partial agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. Thioridazine is a typical antipsychotic with high affinity for dopamine D2 receptors and moderate affinity for serotonin 5-HT2A, alpha1-adrenergic, and histamine H1 receptors.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Chlorzoxazone 500 mg to 750 mg orally three to four times daily.
None Documented
None Documented
Clinical Note
moderateBaclofen + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Baclofen is combined with Fluticasone propionate."
Clinical Note
moderateBaclofen + Clemastine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Clemastine."
Clinical Note
moderateBaclofen + Venlafaxine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Venlafaxine."
Clinical Note
moderateBaclofen + Nefazodone
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
10-12 hours in healthy adults; prolonged to 18-24 hours in hepatic impairment or elderly
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Renal excretion of unchanged drug (70-90%) and glucuronide conjugates; biliary/fecal elimination accounts for <10%
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Baclofen is combined with Nefazodone."